The rapidly changing landscape of respiratory syncytial virus prophylaxis

Joan L Robinson; Jesse Papenburg

doi:10.3138/jammi-2023-05-31

The rapidly changing landscape of respiratory syncytial virus prophylaxis

J Assoc Med Microbiol Infect Dis Can. 2023 Nov 29;8(3):165-171. doi: 10.3138/jammi-2023-05-31. eCollection 2023 Nov.

Authors

Joan L Robinson¹, Jesse Papenburg²

Affiliations

¹ Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
² Department of Pediatrics, McGill University, Montreal, Quebec, Canada.

Abstract
in English, French

The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect young infants has the potential to dramatically decrease RSV hospitalizations in Canada. However, there remain many unanswered questions before optimal use of these products can be assured.

L’homologation du nirsévimab (un anticorps monoclonal anti-VRS qui peut assurer une protection pendant au moins cinq mois après une seule dose) et des vaccins contre le VRS administrés aux personnes enceintes pour protéger les nourrissons au Canada a le potentiel de réduire considérablement les hospitalisations attribuables au VRS au Canada. Cependant, de nombreuses questions restent sans réponse afin de pouvoir garantir une utilisation optimale de ces produits.

Keywords: Respiratory syncytial virus; nirsevimab; palivizumab; prophylaxis; vaccine.

Grants and funding

Funding: No funding was received for this work.

Abstract in English, French

Grants and funding

Abstract
in English, French